Article

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: A Clinical and Managed Care Perspective A CE/CME Supplement to The American Journal of Managed Care

3.0 Credits - CME/CPE | Expires 12/15/2015

This activity is supported by educational grants from Biogen Idec and Teva Pharmaceuticals.

Faculty

Luigi Brunetti, PharmD, MPH

Clinical Associate Professor

Ernest Mario School of Pharmacy

Rutgers, The State University of New Jersey

Piscataway, New Jersey

Samuel F. Hunter, MD, PhD

Director

Novel Pharmaceutics Institute

NeuroNexus Center for Education and Research

Advanced Neurosciences Institute

Franklin, Tennessee

Clinical Assistant Professor

Department of Neurology

Vanderbilt University

Nashville, Tennessee

Megan Maroney, PharmD, BCPP

Clinical Assistant Professor

Department of Pharmacy Practice and Administration

Ernest Mario School of Pharmacy

Rutgers, The State University of New Jersey

Piscataway, New Jersey

Clinical Psychiatric Pharmacist

Monmouth Medical Center

Long Branch, New Jersey

A. Scott Mathis, PharmD

Director of Pharmacy

Monmouth Medical Center

Long Branch, New Jersey

Gary M. Owens, MD

President

Gary Owens Associates

Ocean View, Delaware

Activity Overview

Multiple sclerosis (MS) is a chronic, often debilitating disease of the central nervous system that affects up to 570,000 individuals in the United States and is associated with tremendous clinical, economic, and societal burdens. As MS is a major market driver for the use of specialty pharmacy and a noteworthy contributor to rising healthcare expenditures in the United States, the evolution of clinical and managed care strategies for MS is likely to be heavily impacted by the Affordable Care Act (ACA) and ongoing healthcare reform. This supplement to The American Journal of Managed Care will provide an epidemiological and clinical overview of MS, discuss current and emerging pharmacotherapeutic strategies for the disease, evaluate the burdens of disease, and examine the impact of changing public policies on the management of MS.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Review the socioeconomic profile of patients with MS and the toll of disease on the economic future of affected individuals and their caregivers
  • Discuss current pharmacotherapeutic strategies for MS, including pipeline activity and emerging agents
  • Evaluate the impact of MS on health-related resources, economic burden, and toll on society
  • Discuss the changing public policies affecting the management of MS, and how these policies may impact treatment adherence and future economic burden

Intended Audience

Managed care clinicians and administrators, including physicians, pharmacists, medical and formulary directors, and other managed care professionals involved in the care of patients with multiple sclerosis.

Release date: December 15, 2014

Expiration date: December 15, 2015

Estimated time to complete activity: 3.0 hours

Type of activity: Knowledge

Fee: Free

Physician Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Penn State College of Medicine and Pharmacy Times Office of Continuing Professional Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Penn State College of Medicine designates this enduring material activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Credit

Accreditation Statement

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 3.0 contact hours (0.30 CEUs) under the ACPE universal activity number 0290-9999-14-105-H01-P. The activity is available for CE credit through December 15, 2015.

Obtaining Credit:

Participants must take the pretest, read the journal supplement, and complete the online posttest achieving a passing score of 70% or higher. Once the posttest is submitted each participate will need to complete and submit the online activity evaluation and request their credit before the activity expires on December 15, 2015. Upon completion of the activity evaluation form, you may view your credit within 48 hours at www.mycpemonitor.net.

For Physician credit (CME) only

Physicians Only

Start Activity

For Pharmacy credit (CPE) only

Pharmacists Only

Start Activity

System Requirements

PC-based participants

Required: Windows® 7, Vista, XP, 2003 Server or 2000

Macintosh®-based participants

Required: Mac OS® X 10.4.11 (Tiger®) or newer

For questions about this Internet CPE activity, please contact: ceinfo@pharmacytimes.com.

Privacy Policy and Terms of Use Information: www.pharmacytimes.com/terms_condition.

Related Videos
Io Hui, PhD, researcher at The University of Edinburgh
Adam Colborn, JD, of AMCP
Corey McEwen, PharmD, MS
Daniel Howell, MBBS
1 KOL is featured in this series.
Jonathan Kurman, MD
Tetyana Kendzerska, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo